. Author manuscript; available in PMC: 2011 Jan 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 Jun 22;19(7):1862–1865. doi: 10.1158/1055-9965.EPI-10-0281

Table 2.

TERT SNP genotype and cancer risk.

	OR (95% CI), p-het
TERT rs401681	Breast Cancer `6800 cases, 6608 controls`	Colorectal Cancer `2259 cases, 2246 controls`	Melanoma `782 cases, 999 controls`
CC	1.00 ref	1.00 ref	1.00 ref
CT	1.02 (0.94 - 1.10),0.49	1.09 (0.96 - 1.25), 0.19	1.01 (0.79 - 1.29), 0.95
TT	1.01 (0.92 - 1.12),0.70	1.02 (0.86 - 1.21), 0.80	0.98 (0.70 - 1.37), 0.90
Per T allele	1.01 (0.96 - 1.06) p-trend = 0.64	1.02 (0.94 - 1.11) p-trend = 0.66	0.99 (0.84 - 1.17) p-trend = 0.91

Genotype frequencies in cases and controls were compared using a 2 degree of freedom (df) χ² test for heterogeneity (p-het) and a 1 df Cochran-Armitage χ² test for trend in risk by T allele dose (p-trend). Genotype-specific risks were estimated as odds ratios (OR), with associated 95% confidence intervals (95% CI), using unconditional logistic regression. For each study, the deviation of genotype distribution in controls from Hardy-Weinberg equilibrium was assessed by a χ² test with one degree of freedom (data not shown).